{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:50:50Z","timestamp":1794862250607,"version":"4.9.1"},"reference-count":58,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Acute myeloid leukemias (AML) are severe hematomalignancies with dismal prognosis. The post-translational modification SUMOylation plays key roles in leukemogenesis and AML response to therapies. Here, we show that TAK-981 (subasumstat), a first-in-class SUMOylation inhibitor, is endowed with potent anti-leukemic activity in various preclinical models of AML. TAK-981 targets AML cell lines and patient blast cells in vitro and in vivo in xenografted mice with minimal toxicity on normal hematopoietic cells. Moreover, it synergizes with 5-azacytidine (AZA), a DNA-hypomethylating agent now used in combination with the BCL-2 inhibitor venetoclax to treat AML patients unfit for standard chemotherapies. Interestingly, TAK-981+AZA combination shows higher anti-leukemic activity than AZA+venetoclax combination both in vitro and in vivo, at least in the models tested. Mechanistically, TAK-981 potentiates the transcriptional reprogramming induced by AZA, promoting apoptosis, alteration of the cell cycle and differentiation of the leukemic cells. In addition, TAK-981+AZA treatment induces many genes linked to inflammation and immune response pathways. In particular, this leads to the secretion of type-I interferon by AML cells. Finally, TAK-981+AZA induces the expression of natural killer-activating ligands (MICA\/B) and adhesion proteins (ICAM-1) at the surface of AML cells. Consistently, TAK-981+AZA-treated AML cells activate natural killer cells and increase their cytotoxic activity. Targeting SUMOylation with TAK-981 may thus be a promising strategy to both sensitize AML cells to AZA and reduce their immune-escape capacities.<\/jats:p>","DOI":"10.3324\/haematol.2023.282704","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:07:00Z","timestamp":1692806820000},"page":"98-114","source":"Crossref","is-referenced-by-count":15,"title":["SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Ludovic","family":"Gabellier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"De Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehuli","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Hallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mays","family":"Aqrouq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Buonocore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Recasens-Zorzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiga\u00efl","family":"Delort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Piechaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Temp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bossis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"56018","doi-asserted-by":"crossref","unstructured":"Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016; 5(3):33.","DOI":"10.3390\/jcm5030033"},{"key":"56019","doi-asserted-by":"crossref","unstructured":"Ahmadmehrabi K, Haque AR, Aleem A, Griffiths EA, Roloff GW. Targeted therapies for the evolving molecular landscape of acute myeloid leukemia. Cancers (Basel). 2021; 13(18):4646.","DOI":"10.3390\/cancers13184646"},{"key":"56020","doi-asserted-by":"crossref","unstructured":"Ciotti G, Marconi G, Martinelli G. Hypomethylating agent-based Ccmbination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia. Front Oncol. 2022; 11:810387.","DOI":"10.3389\/fonc.2021.810387"},{"key":"56021","doi-asserted-by":"crossref","unstructured":"Liu JCY, K\u00fchbacher U, Larsen NB. Mechanism and function of DNA replication-independent DNA-protein crosslink repair via the SUMO-RNF4 pathway. EMBO J. 2021; 40(18):e107413.","DOI":"10.15252\/embj.2020107413"},{"key":"56022","doi-asserted-by":"crossref","unstructured":"Lund K, Cole JJ, VanderKraats ND. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol. 2014; 15(8):406.","DOI":"10.1186\/s13059-014-0406-2"},{"key":"56023","doi-asserted-by":"crossref","unstructured":"Dombret H, Seymour JF, Butrym A. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts. Blood. 2015; 126(3):291-299.","DOI":"10.1182\/blood-2015-01-621664"},{"key":"56024","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"56025","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"56026","doi-asserted-by":"crossref","unstructured":"Garciaz S, Saillard C, Hicheri Y, Hospital M-A, Vey N. Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance. Cancers. 2021; 13(22):5608.","DOI":"10.3390\/cancers13225608"},{"key":"56027","doi-asserted-by":"crossref","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022; 5(2):380-400.","DOI":"10.20517\/cdr.2021.125"},{"key":"56028","doi-asserted-by":"crossref","unstructured":"Vertegaal ACO. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 2022; 23(11):715-731.","DOI":"10.1038\/s41580-022-00500-y"},{"key":"56029","doi-asserted-by":"crossref","unstructured":"Hendriks IA, Lyon D, Young C, Jensen LJ, Vertegaal ACO, Nielsen ML. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat Struct Mol Biol. 2017; 24(3):325-336.","DOI":"10.1038\/nsmb.3366"},{"key":"56030","doi-asserted-by":"crossref","unstructured":"Hendriks IA, Lyon D, Su D. Site-specific characterization of endogenous SUMOylation across species and organs. Nat Commun. 2018; 9(1):2456.","DOI":"10.1038\/s41467-018-04957-4"},{"key":"56031","doi-asserted-by":"crossref","unstructured":"Pichler A, Fatouros C, Lee H, Eisenhardt N. SUMO conjugation - a mechanistic view. Biomol Concepts. 2017; 8(1):13-36.","DOI":"10.1515\/bmc-2016-0030"},{"key":"56032","doi-asserted-by":"crossref","unstructured":"Boulanger M, Chakraborty M, Temp\u00e9 D, Piechaczyk M, Bossis G. SUMO and transcriptional regulation: the lessons of large-scale proteomic, modifomic and genomic studies. Molecules. 2021; 26(4):828.","DOI":"10.3390\/molecules26040828"},{"key":"56033","doi-asserted-by":"crossref","unstructured":"Rosonina E. A conserved role for transcription factor sumoylation in binding-site selection. Curr Genet. 2019; 65(6):1307-1312.","DOI":"10.1007\/s00294-019-00992-w"},{"key":"56034","doi-asserted-by":"crossref","unstructured":"Bossis G, Sarry J-E, Kifagi C. The ROS\/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep. 2014; 7(6):1815-1823.","DOI":"10.1016\/j.celrep.2014.05.016"},{"key":"56035","doi-asserted-by":"crossref","unstructured":"Baik H, Boulanger M, Hosseini M. Targeting the SUMO pathway primes all-trans retinoic acid\u2013induced differentiation of nonpromyelocytic acute myeloid leukemias. Cancer Res. 2018; 78(10):2601-2613.","DOI":"10.1158\/0008-5472.CAN-17-3361"},{"key":"56036","doi-asserted-by":"crossref","unstructured":"Langston SP, Grossman S, England D. Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer. J Med Chem. 2021; 64(5):2501-2520.","DOI":"10.1021\/acs.jmedchem.0c01491"},{"key":"56037","doi-asserted-by":"crossref","unstructured":"Lightcap ES, Yu P, Grossman S. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Sci Transl Med. 2021; 13(611):eaba7791.","DOI":"10.1126\/scitranslmed.aba7791"},{"key":"56038","doi-asserted-by":"crossref","unstructured":"Kumar S, Schoonderwoerd MJA, Kroonen JS. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 2022; 71(11):2266-2283.","DOI":"10.1136\/gutjnl-2021-324834"},{"key":"56039","doi-asserted-by":"crossref","unstructured":"Demel UM, B\u00f6ger M, Yousefian S. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer. J Clin Invest. 2022; 132(9):e152383.","DOI":"10.1172\/JCI152383"},{"key":"56040","doi-asserted-by":"crossref","unstructured":"Nakamura A, Grossman S, Song K. SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood. 2022; 139(18):2770-2781.","DOI":"10.1182\/blood.2021014267"},{"key":"56041","doi-asserted-by":"crossref","unstructured":"Demel UM, Wirth M, Yousefian S. Small molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy. Haematologica. 2023; 108(2):555-567.","DOI":"10.3324\/haematol.2022.280995"},{"key":"56042","doi-asserted-by":"crossref","unstructured":"Du L, Liu W, Pichiorri F, Rosen ST. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene Ther. 2022; 30(4):567-574.","DOI":"10.1038\/s41417-022-00450-9"},{"key":"56043","doi-asserted-by":"crossref","unstructured":"Du L, Liu W, Aldana-Masangkay G. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. J Exp Clin Cancer Res. 2022; 41(1):1-16.","DOI":"10.1186\/s13046-021-02226-9"},{"key":"56044","doi-asserted-by":"crossref","unstructured":"Kim HS, Kim B-R, Dao TTP. TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently. Blood Adv. 2023; 7(13):3155-3168.","DOI":"10.1182\/bloodadvances.2022007956"},{"key":"56045","doi-asserted-by":"crossref","unstructured":"Paolillo R, Boulanger M, G\u00e2tel P. The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias. Haematologica. 2022; 107(11):2562-2575.","DOI":"10.3324\/haematol.2021.279889"},{"key":"56046","doi-asserted-by":"crossref","unstructured":"G\u00e2tel P, Brockly F, Reynes C. Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies. Life Sci Alliance. 2020; 3(6):e201900577.","DOI":"10.26508\/lsa.201900577"},{"key":"56047","doi-asserted-by":"crossref","unstructured":"Recasens-Zorzo C, G\u00e2tel P, Brockly F, Bossis G. A microbead-based flow cytometry assay to assess the activity of ubiquitin and ubiquitin-like conjugating enzymes. Methods Mol Biol. 2023; 2602:65-79.","DOI":"10.1007\/978-1-0716-2859-1_5"},{"key":"56048","doi-asserted-by":"crossref","unstructured":"Gartel AL, Ye X, Goufman E. Myc represses the p21(WAF1\/ CIP1) promoter and interacts with Sp1\/Sp3. Proc Natl Acad Sci U S A. 2001; 98(8):4510-4515.","DOI":"10.1073\/pnas.081074898"},{"key":"56049","doi-asserted-by":"crossref","unstructured":"Stubbins RJ, Karsan A. Differentiation therapy for myeloid malignancies: beyond cytotoxicity. Blood Cancer J. 2021; 11(12):1-9.","DOI":"10.1038\/s41408-021-00584-3"},{"key":"56050","doi-asserted-by":"crossref","unstructured":"Rahmani S, Yazdanpanah N, Rezaei N. Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunol Immunother. 2022; 71(12):2849-2867.","DOI":"10.1007\/s00262-022-03217-1"},{"key":"56051","doi-asserted-by":"crossref","unstructured":"Allende-Vega N, Marco Brualla J, Falvo P. Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). Sci Rep. 2022; 12(1):1341.","DOI":"10.1038\/s41598-022-05470-x"},{"key":"56052","doi-asserted-by":"crossref","unstructured":"Carlsten M, J\u00e4r\u00e5s M. Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front Immunol. 2019; 10:2357.","DOI":"10.3389\/fimmu.2019.02357"},{"key":"56053","doi-asserted-by":"crossref","unstructured":"Seeler J-S, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017; 17(3):184-197.","DOI":"10.1038\/nrc.2016.143"},{"key":"56054","doi-asserted-by":"crossref","unstructured":"Boulanger M, Paolillo R, Piechaczyk M, Bossis G. The SUMO pathway in hematomalignancies and their response to therapies. Int J Mol Sci. 2019; 20(16):3895.","DOI":"10.3390\/ijms20163895"},{"key":"56055","doi-asserted-by":"crossref","unstructured":"Zhou P, Chen X, Li M. 2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. Biochem Biophys Res Commun. 2019; 513(4):1063-1069.","DOI":"10.1016\/j.bbrc.2019.04.079"},{"key":"56056","doi-asserted-by":"crossref","unstructured":"Benoit YD, Mitchell RR, Wang W. Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics. Cell Chem Biol. 2021; 28(10):1394-1406.","DOI":"10.1016\/j.chembiol.2021.04.014"},{"key":"56057","doi-asserted-by":"crossref","unstructured":"Ishii H, Yano S. New therapeutic strategies for adult acute myeloid leukemia. Cancers (Basel). 2022; 14(11):2806.","DOI":"10.3390\/cancers14112806"},{"key":"56058","doi-asserted-by":"crossref","unstructured":"Pei S, Pollyea DA, Gustafson A. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020; 10(4):536-551.","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"56059","doi-asserted-by":"crossref","unstructured":"Ryu H-Y, Hochstrasser M. Histone sumoylation and chromatin dynamics. Nucleic Acids Res. 2021; 49(11):6043-6052.","DOI":"10.1093\/nar\/gkab280"},{"key":"56060","doi-asserted-by":"crossref","unstructured":"Seifert A, Schofield P, Barton GJ, Hay RT. Proteotoxic stress reprograms the chromatin landscape of SUMO modification. Sci Signal. 2015; 8(384):rs7.","DOI":"10.1126\/scisignal.aaa2213"},{"key":"56061","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Prieto R, Eifler-Olivi K, Claessens LA. Global non-covalent SUMO interaction networks reveal SUMO-dependent stabilization of the non-homologous end joining complex. Cell Rep. 2021; 34(4):108691.","DOI":"10.1016\/j.celrep.2021.108691"},{"key":"56062","doi-asserted-by":"crossref","unstructured":"Lascorz J, Codina-Fabra J, Reverter D, Torres-Rosell J. SUMO-SIM interactions: from structure to biological functions. Semin Cell Dev Biol. 2022; 132:193-202.","DOI":"10.1016\/j.semcdb.2021.11.007"},{"key":"56063","doi-asserted-by":"crossref","unstructured":"Ouyang J, Shi Y, Valin A, Xuan Y, Gill G. Direct binding of CoREST1 to SUMO-2\/3 contributes to gene-specific repression by the LSD1\/CoREST1\/HDAC complex. Mol Cell. 2009; 34(2):145-154.","DOI":"10.1016\/j.molcel.2009.03.013"},{"key":"56064","doi-asserted-by":"crossref","unstructured":"Hua G, Ganti KP, Chambon P. Glucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT\/NCoR1-HDAC3 repressing complex. Proc Natl Acad Sci U S A. 2016; 113(5):E635-E643.","DOI":"10.1073\/pnas.1522826113"},{"key":"56065","doi-asserted-by":"crossref","unstructured":"Pascual G, Fong AL, Ogawa S. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-\u03b3. Nature. 2005; 437(7059):759-763.","DOI":"10.1038\/nature03988"},{"key":"56066","doi-asserted-by":"crossref","unstructured":"Ivanov AV, Peng H, Yurchenko V. PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Mol Cell. 2007; 28(5):823-837.","DOI":"10.1016\/j.molcel.2007.11.012"},{"key":"56067","doi-asserted-by":"crossref","unstructured":"Boulanger M, Aqrouq M, Temp\u00e9 D. DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias. Nucleic Acids Res. 2023; 51(16):8413-8433.","DOI":"10.1093\/nar\/gkad581"},{"key":"56068","doi-asserted-by":"crossref","unstructured":"Borgermann N, Ackermann L, Schwertman P. SUMOylation promotes protective responses to DNA-protein crosslinks. EMBO J. 2019; 38(8):e101496.","DOI":"10.15252\/embj.2019101496"},{"key":"56069","doi-asserted-by":"crossref","unstructured":"Kroonen JS, de Graaf IJ, Kumar S. Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies. Leukemia. 2023; 37(4):864-876.","DOI":"10.1038\/s41375-023-01838-8"},{"key":"56070","doi-asserted-by":"crossref","unstructured":"Hollenbach PW, Nguyen AN, Brady H. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010; 5(2):e9001.","DOI":"10.1371\/journal.pone.0009001"},{"key":"56071","doi-asserted-by":"crossref","unstructured":"Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021; 11(6):1-9.","DOI":"10.1038\/s41408-021-00514-3"},{"key":"56072","doi-asserted-by":"crossref","unstructured":"Madan V, Koeffler HP. Differentiation therapy of myeloid leukemia: four decades of development. Haematologica. 2021; 106(1):26-38.","DOI":"10.3324\/haematol.2020.262121"},{"key":"56073","doi-asserted-by":"crossref","unstructured":"Roulois D, Loo Yau H, Singhania R. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015; 162(5):961-973.","DOI":"10.1016\/j.cell.2015.07.056"},{"key":"56074","doi-asserted-by":"crossref","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A. Inhibiting DNA Methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015; 162(5):974-986.","DOI":"10.1016\/j.cell.2015.07.011"},{"key":"56075","doi-asserted-by":"crossref","unstructured":"Aric\u00f2 E, Castiello L, Capone I, Gabriele L, Belardelli F. Type I interferons and cancer: an evolving story demanding novel clinical applications. Cancers (Basel). 2019; 11(12):1943.","DOI":"10.3390\/cancers11121943"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282704\/76012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282704\/76425","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11222\/76012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:42Z","timestamp":1794045882000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282704","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}